
Treatment Robotics, a San Francisco medtech treating stroke sufferers remotely, and cofounded by Perth-born physician David Bell, has raised US$62 million (A$92m) in a Sequence B, backed by a variety of Australian enterprise funds.
US enterprise agency DCVC led the spherical, with present backers Blackbird, Tony Fadell’s Construct Collective, Divergent Capital and KdT Ventures chipping in alongside the the College of California’s funding workplace, Skip Capital and tremendous fund Hostplus as new buyers.
Treatment beforehand raised US$35 million throughout its Seed and Sequence A rounds.
The recent capital is for a medical trial throughout the College of California’s community by a surgical robotic designed to let specialists deal with stroke sufferers a whole bunch of kilometres away. The medtech is searching for US Meals and Drug Administration approval for procedures on the blood vessels supplying the mind. It additionally plans to put prototype robots with medical companions, together with the Australian Stroke Alliance.
Bell spent eight years in medication, together with cardiac surgical procedure and air retrieval, earlier than learning at Stanford, the place he met his cofounder and CTO Jake Sganga. In 2021, the pair lined a storage in Venice Seaside with lead, purchased a second-hand X-ray machine and had a colleague in Berkeley function their prototype remotely.
“This funding will enable our world-leading {hardware}, software program, and machine studying groups to progress the N1 system in the direction of medical trials and potential FDA approval, whereas additionally growing extra options together with full autonomy,” Sganga stated.
The N1 robotic lets a specialist at a console steer a catheter by way of a affected person’s blood vessels. Its software program makes use of machine studying to analyse scans, simulate procedures and match a 3D map of the vessels to reside X-ray photographs. The workforce can be growing autonomous capabilities.
In August 2025, a Toronto neurosurgeon used the N1 to carry out diagnostic angiograms on two sufferers at a hospital 6km away. A medical workforce stayed with every affected person whereas Pereira guided the catheter to verify for narrowed or blocked vessels.
The N1 has but to safe approval for routine medical use wherever. In Australia, Treatment and the Stroke Alliance need specialists in main cities to have the ability to take away a clot whereas the affected person remains to be at their regional hospital.